The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Discover Arteris, Inc.'s standout Q4 2024 results, including record ACV, FlexGen Smart NoC launch, and 2025 growth outlook.

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...